Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 9
Submit an article Journal homepage
96
Views
0
CrossRef citations to date
0
Altmetric
Commentaries

Response-adapted approach in newly diagnosed myeloma: when less is at least equal

Elisabet E. Manasancha Department of Lymphoma and Myeloma, MD Anderson Cancer Center, University of Texas, Houston, TX, USACorrespondence[email protected]
&
Morie A. Gertzb Division of Hematology, Mayo Clinic, Rochester, MN, USA
Pages 2021-2022 | Published online: 12 Sep 2022

References

  • Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–1107.
  • Survival rate multiple myeloma. [cited 2022 Aug 28]. https://www.cancer.org/cancer/multiple-myeloma/detection-diagnosis-staging/survival-rates.html.
  • Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936–945.
  • Mateos MV, Nooka AK, Larson SM. Moving toward a cure for myeloma. Am Soc Clin Oncol Educ Book. 2022;42:1–12.
  • Lahoud OB, Nguyen LH, et al. Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplatation in newly diagnosed multiple myeloma: a case for response-adapted approach. Leuk Lymphoma. 2022;63(9):2126–2135.
  • Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15(3):333–342.
  • Jonsdottir G, Lund SH, Bjorkholm M, et al. Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study. Haematologica. 2016;101(4):e145-148–e148.
  • Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311–1320.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.